Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to Sell at StockNews.com

StockNews.com cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research report report published on Saturday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Up 0.4 %

NASDAQ:ORMP opened at $2.45 on Friday. Oramed Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $3.67. The stock has a fifty day simple moving average of $2.38 and a 200-day simple moving average of $2.41. The company has a market capitalization of $98.76 million, a PE ratio of 22.27 and a beta of 1.67.

Institutional Trading of Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ORMP. XTX Topco Ltd acquired a new position in Oramed Pharmaceuticals in the 2nd quarter valued at about $40,000. Dimensional Fund Advisors LP raised its position in shares of Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 10,774 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Oramed Pharmaceuticals in the third quarter valued at approximately $272,000. Renaissance Technologies LLC lifted its stake in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the period. Finally, Murchinson Ltd. boosted its position in Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after acquiring an additional 320,495 shares during the last quarter. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.